Strategic partnerships ChemDiv has a history of collaborative development models and co-investment with pharma and biotech partners, plus ongoing partnerships with institutions and industry players. This presents opportunities to position ChemDiv as a preferred partner for asset co-development, asset rescue, and expanded discovery-to-clinic programs.

Integrated capabilities As a fully integrated Target-to-Market CRO with in-house chemistry, discovery, and early clinical development, ChemDiv can bundle end-to-end services for clients looking to accelerate programs, potentially enabling premium pricing and streamlined vendor management for new projects in CNS, oncology, inflammatory, metabolic, and infectious diseases.

Global reach Headquartered in San Diego with a global footprint and extensive academic partnerships, ChemDiv can attract multinational sponsors seeking regional presence and scalable resourcing, offering geographically flexible teams, faster start-up, and diverse access to HTS and screening libraries.

Proprietary assets ChemDiv maintains a large inventory of greenable stock compounds and invests in proprietary chemistry and discovery platforms, which can be leveraged as differentiators for customers needing fast-hit generation, specialized libraries, or unique screening options to de-risk early discovery.

Recent growth signals New CMC service launches, extended partnerships (e.g., Mondego Bio) and leadership expansion indicate a growth and capability expansion trajectory, suggesting sales opportunities around new service offerings, expanded early development capabilities, and cross-sell into integrated programs with existing clients.